Investors

Directors’ Dealings

Share dealings of the Board of Executive Directors and Supervisory Board

(Obligatory reportable and publishable directors’ dealings under Article 19(1) of the E.U. Market Abuse Regulation 596/2014 (MAR))

As legally stipulated by Article 19(1) MAR, all members of the Board of Executive Directors and the Supervisory Board as well as close family relatives are required to disclose the purchase or sale of financial instruments of BASF SE (for example, shares, bonds, options, forward contracts, swaps) to the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) and to the company if transactions within the calendar year exceed the threshold of €20,000. In 2023, a total of 11 purchases by members of the Board of Executive Directors and the Supervisory Board of BASF SE and members of their families subject to disclosure were reported as directors’ dealings, involving between 800 and 3,400 BASF shares or BASF ADRs (American Depositary Receipts). The price per share was between €45.52 and €48.76. The volume of the individual transactions was between €34,134.94 and €154,779.

Downloads

Archive Directors’ Dealings

Share ownership by members of the Board of Executive Directors and the Supervisory Board

No member of the Board of Executive Directors or the Supervisory Board owns shares in BASF SE and related options or other derivatives that account for 1% or more of the share capital. Furthermore, the total volume of BASF SE shares and related financial instruments held by all members of the Board of Executive Directors and the Supervisory Board accounts for less than 1% of the shares issued by the company.

Closed periods

30 calendar days before public disclosure of a quarterly statement on the first or third quarter, half-year financial report or annual report of BASF SE.

Next closed periods:

January 29, 2025 to February 28, 2025
April 2, 2025 to May 2, 2025
June 30, 2025 to July 30, 2025
September 29, 2025 to October 29, 2025

Managers’ transactions

Name	Date and Place of Transaction	Type of Transaction	Price per Item	Total Amount/ Currency	Reason for Disclosure Requirement/ Position	Description of Financial Instrument	ISIN
Dr. Dirk Elvermann	12/03/2024 Tradegate	Purchase	€43.88	€105,316.00	Board Member	Shares of BASF SE	DE000BASF111
Michael Heinz	10/23/2024 Stuttgart	Purchase	€45.99	€99,936.27	Board Member	Shares of BASF SE	DE000BASF111
Dr. Dirk Elvermann	08/16/2024 Tradegate	Purchase	€42.61	€55,393.00	Board Member	Shares of BASF SE	DE000BASF111
Anup Kothari	08/05/2024 OTCQX	Purchase	$11.16	$249,995.16	Board Member	BASF ADR	CUSIP 055262505
Anup Kothari	06/14/2024 OTCQX	Purchase	$11.89	$249,987.25	Board Member	BASF ADR	CUSIP 055262505
Dr. Dirk Elvermann	06/10/2024 Tradegate	Purchase	€46.33	€99,610.00	Board Member	Shares of BASF SE	DE000BASF111
Dr. Katja Scharpwinkel	05/27/2024 Tradegate	Purchase	€48.53	€97,050.00	Board Member	Shares of BASF SE	DE000BASF111
Dr. Kurt Bock	04/26/2024 Xetra	Purchase	€48.42	€124,963.24	Supervisory Board Member	Shares of BASF SE	DE000BASF111
Prof. Dr. Stefan Asenkerschbaumer	04/26/2024 Xetra	Purchase	€48.42	€72,915.40	Supervisory Board Member	Shares of BASF SE	DE000BASF111
Alessandra Genco	04/26/2024 Xetra	Purchase	€48.42	€49,965.93	Supervisory Board Member	Shares of BASF SE	DE000BASF111
Liming Chen	04/26/2024 Xetra	Purchase	€48.42	€49,965.93	Supervisory Board Member	Shares of BASF SE	DE000BASF111
Prof. Dr. Thomas Carell	04/26/2024 Xetra	Purchase	€48.42	€49,965.93	Supervisory Board Member	Shares of BASF SE	DE000BASF111
Dr. Stephan Kothrade	04/26/2024 Tradegate	Purchase	€48.57	€242,865.00	Board Member	Shares of BASF SE	DE000BASF111
Dr. Markus Kamieth	03/04/2024 Xetra	Purchase	€46.98	€999,666.13	Board Member	Shares of BASF SE	DE000BASF111
Dr. Dirk Elvermann	01/24/2024¹ Tradegate	Purchase	€43.72	€109,306.50	Board Member	Shares of BASF SE	DE000BASF111
Dr. Stephan Kothrade	01/22/2024¹ Tradegate	Purchase	€42.65	€264,430.00	Board Member	Shares of BASF SE	DE000BASF111
¹ As BASF SE disclosed the preliminary figures for FY 2023 on January 19, 2024 via an ad-hoc release, the closed period for FY 2023/Q4 2023 already ended prematurely on this date.